Cognition Therapeutics, Inc. Operating Income
Cognition Therapeutics, Inc. (CGTX) reported Operating Income of -$7.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-07
- Cognition Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$7.74M.
- Cognition Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$8.82M.
- Cognition Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$13.67M.
- Cognition Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$6.38M.
- Cognition Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$47.80M.
- Cognition Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$53.97M.
- Cognition Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$50.72M.
- Cognition Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$43.55M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.74M 10-Q · filed 2026-08-07 | -$16.55M 10-Q · filed 2026-08-07 | -$30.23M derived: sum of 3 quarters · filed 2026-08-07 | -$36.60M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$8.82M 10-Q · filed 2026-05-08 | -$22.49M derived: sum of 2 quarters · filed 2026-05-08 | -$28.86M derived: sum of 3 quarters · filed 2026-05-08 | -$42.84M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$13.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$20.05M derived: sum of 2 quarters · filed 2026-03-26 | -$34.02M derived: sum of 3 quarters · filed 2026-08-07 | -$47.80M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$6.38M 10-Q · filed 2025-11-06 | -$20.35M derived: sum of 2 quarters · filed 2026-08-07 | -$34.13M 10-Q · filed 2025-11-06 | -$44.85M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$13.98M 10-Q · filed 2026-08-07 | -$27.75M 10-Q · filed 2026-08-07 | -$38.48M derived: sum of 3 quarters · filed 2026-08-07 | -$52.94M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$13.78M 10-Q · filed 2026-05-08 | -$24.50M derived: sum of 2 quarters · filed 2026-05-08 | -$38.96M derived: sum of 3 quarters · filed 2026-05-08 | -$53.64M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$10.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$25.19M derived: sum of 2 quarters · filed 2026-03-26 | -$39.86M derived: sum of 3 quarters · filed 2026-03-26 | -$53.97M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$14.46M 10-Q · filed 2025-11-06 | -$29.14M derived: sum of 2 quarters · filed 2025-11-06 | -$43.24M 10-Q · filed 2025-11-06 | -$58.43M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$14.68M 10-Q · filed 2025-08-07 | -$28.78M 10-Q · filed 2025-08-07 | -$43.97M derived: sum of 3 quarters · filed 2025-08-07 | -$58.71M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$14.10M 10-Q · filed 2025-05-07 | -$29.29M derived: sum of 2 quarters · filed 2025-05-07 | -$44.04M derived: sum of 3 quarters · filed 2025-05-07 | -$55.85M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$15.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$29.93M derived: sum of 2 quarters · filed 2025-03-20 | -$41.75M derived: sum of 3 quarters · filed 2025-03-20 | -$50.72M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$14.74M 10-Q · filed 2024-11-13 | -$26.56M derived: sum of 2 quarters · filed 2024-11-13 | -$35.53M 10-Q · filed 2024-11-13 | -$44.84M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$11.82M 10-Q · filed 2024-08-08 | -$20.79M 10-Q · filed 2024-08-08 | -$30.09M derived: sum of 3 quarters · filed 2024-08-08 | -$42.72M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$8.97M 10-Q · filed 2024-05-07 | -$18.27M derived: sum of 2 quarters · filed 2024-05-07 | -$30.90M derived: sum of 3 quarters · filed 2024-05-07 | -$43.11M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$21.93M derived: sum of 2 quarters · filed 2024-03-26 | -$34.14M derived: sum of 3 quarters · filed 2024-03-26 | -$43.55M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$12.63M 10-Q · filed 2023-11-02 | -$24.84M derived: sum of 2 quarters · filed 2023-11-02 | -$34.25M 10-Q · filed 2023-11-02 | -$46.06M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$12.21M 10-Q · filed 2023-08-08 | -$21.63M 10-Q · filed 2023-08-08 | -$33.43M derived: sum of 3 quarters · filed 2023-08-08 | -$38.66M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$9.41M 10-Q · filed 2023-05-04 | -$21.22M derived: sum of 2 quarters · filed 2023-05-04 | -$26.44M derived: sum of 3 quarters · filed 2023-05-04 | -$32.43M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$11.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$17.03M derived: sum of 2 quarters · filed 2023-03-23 | -$23.02M derived: sum of 3 quarters · filed 2023-03-23 | -$28.60M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$5.22M 10-Q · filed 2022-11-14 | -$11.21M derived: sum of 2 quarters · filed 2022-11-14 | -$16.79M 10-Q · filed 2022-11-14 | -$20.91M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$5.98M 10-Q · filed 2022-08-09 | -$11.57M 10-Q · filed 2022-08-09 | -$15.69M derived: sum of 3 quarters · filed 2022-08-09 | -$20.15M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$5.58M 10-Q · filed 2022-05-11 | -$9.70M derived: sum of 2 quarters · filed 2022-05-11 | -$14.16M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$8.58M derived: sum of 2 quarters · filed 2022-03-30 | -$17.41M 10-K · filed 2022-03-30 | |
| 2020-09-30 | -$4.46M 10-Q · filed 2021-11-17 | -$13.29M 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |